- Record: found
- Abstract: found
- Article: not found
Screening for epidermal growth factor receptor mutations in lung cancer.
Rafael Rosell
1 ,
Teresa Moran ,
Cristina Queralt ,
Rut Porta ,
Felipe Cardenal ,
Carlos Camps ,
Margarita Majem ,
Guillermo Lopez-Vivanco ,
Dolores Isla ,
Mariano Provencio ,
Amelia Insa ,
Bartomeu Massuti ,
Jose Luis Gonzalez-Larriba ,
Luis Paz-Ares ,
Isabel Bover ,
Rosario Garcia-Campelo ,
Miguel Angel Moreno ,
Silvia Catot ,
Christian Rolfo ,
Noemi Reguart ,
Ramon Palmero ,
José Miguel Sánchez ,
Roman Bastus ,
Clara Mayo ,
Jordi Bertran-Alamillo ,
Miguel Angel Molina ,
Jose Javier Sanchez ,
Miquel Taron
Sep 03 2009
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the association between the mutations and the outcome of erlotinib treatment.